|
ES2600460T3
(es)
|
2005-05-10 |
2017-02-09 |
Intermune, Inc. |
Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
|
|
HRP20170103T1
(hr)
*
|
2005-12-21 |
2017-03-24 |
Janssen Pharmaceutica N.V. |
Triazolopiridazini kao modulatori tirozin kinaze
|
|
CA2651979A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Triazolopyridazine derivatives
|
|
US8163760B2
(en)
|
2006-06-22 |
2012-04-24 |
Prana Biotechnology Limited |
Use of pyridopyrimidine compounds in the treatment of gliomas
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
*
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
CA2657931A1
(en)
*
|
2006-07-18 |
2008-01-24 |
Cytovia, Inc. |
3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
EP2057164A1
(en)
|
2006-08-07 |
2009-05-13 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
JP2010519174A
(ja)
|
2006-09-18 |
2010-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔの複素環阻害薬およびその使用方法
|
|
RS54510B1
(sr)
|
2006-11-22 |
2016-06-30 |
Incyte Holdings Corporation |
Imidazotriazini i imidazopirimidini kao inhibitori kinaze
|
|
CA2681162C
(en)
|
2007-03-15 |
2015-11-24 |
Novartis Ag |
Benzyl and pyridine derivatives as modulators of hedgehog pathway
|
|
EP2162132A4
(en)
*
|
2007-05-21 |
2013-01-16 |
Sgx Pharmaceuticals Inc |
Heterocyclic kinase modulators
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
WO2009005675A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Abbott Laboratories |
Novel triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
HUE025976T2
(en)
|
2007-09-27 |
2016-05-30 |
Fund Centro Nac De Investig Oncologicas Carlos Iii |
Imidazolothiadiazoles for use as protein kinase inhibitors
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
UY31676A1
(es)
|
2008-02-28 |
2009-09-30 |
|
"derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
TWI472529B
(zh)
|
2008-05-21 |
2015-02-11 |
Incyte Corp |
２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
|
|
CN102099036B
(zh)
|
2008-06-03 |
2015-05-27 |
英特芒尼公司 |
用于治疗炎性疾患和纤维化疾患的化合物和方法
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
JP5596047B2
(ja)
*
|
2008-11-19 |
2014-09-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
|
|
US8592448B2
(en)
|
2008-11-20 |
2013-11-26 |
OSI Pharmaceuticals, LLC |
Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
SI2361250T1
(sl)
|
2008-12-22 |
2013-12-31 |
Merck Patent Gmbh |
Nove polimorfne oblike 6-(1-metil-1h-pirazol-4-il)-2-(3-(5-(2-morfolin-4-il-etoksi)-pirimidin- 2-il)-benzil)-2h-piridazin-3-on dihidrogenfosfata in postopki za proizvodnjo le-tega
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
MX2011008452A
(es)
|
2009-02-10 |
2011-12-16 |
Astrazeneca Ab |
Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
|
|
WO2010104843A2
(en)
*
|
2009-03-09 |
2010-09-16 |
The Regents Of The University Of California |
Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
|
|
NZ595674A
(en)
|
2009-04-02 |
2012-12-21 |
Ct Nac Investigaciones Oncologicas Cnio |
Imidazo[2,1-b][1,3,4]thiadiazole derivatives
|
|
CA2762479A1
(en)
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-met protein kinase
|
|
EP2435444A1
(en)
|
2009-05-28 |
2012-04-04 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-met protein kinase
|
|
NZ596616A
(en)
*
|
2009-05-28 |
2013-05-31 |
Vertex Pharma |
Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
UA108618C2
(uk)
*
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
CA2771432A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
|
EA030141B1
(ru)
*
|
2009-12-31 |
2018-06-29 |
Хатчисон Медифарма Лимитед |
Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
NZ604306A
(en)
|
2010-05-17 |
2015-02-27 |
Incozen Therapeutics Pvt Ltd |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
JP2013527195A
(ja)
*
|
2010-05-27 |
2013-06-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
|
|
US20130315895A1
(en)
|
2010-07-01 |
2013-11-28 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
JP2014513724A
(ja)
|
2011-05-16 |
2014-06-05 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
融合二環キナーゼ阻害剤
|
|
CN103917529B
(zh)
|
2011-11-11 |
2016-08-17 |
辉瑞大药厂 |
2-硫代嘧啶酮类
|
|
EP2822931B1
(en)
|
2012-03-09 |
2017-05-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
WO2013138617A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
CN107082779A
(zh)
|
2012-03-30 |
2017-08-22 |
理森制药股份公司 |
作为c‑met 蛋白激酶调节剂的新化合物
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
SG11201504622PA
(en)
|
2012-12-20 |
2015-07-30 |
Inception 2 Inc |
Triazolone compounds and uses thereof
|
|
CN105579440A
(zh)
|
2013-09-06 |
2016-05-11 |
因森普深2公司 |
三唑酮化合物及其应用
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
EP3053923B1
(en)
|
2013-09-30 |
2018-04-11 |
Korea Research Institute of Chemical Technology |
Triazolopyrazine derivatives as tyrosin kinase inhibitors
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
MX382781B
(es)
|
2014-04-02 |
2025-03-13 |
Intermune Inc |
Piridinonas anti-fibroticas.
|
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
TWI703133B
(zh)
|
2014-12-23 |
2020-09-01 |
美商艾克斯基製藥公司 |
３,５-二胺基吡唑激酶抑制劑
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
US10363254B2
(en)
|
2015-03-31 |
2019-07-30 |
University Of Vermont And State Agricultural College |
Methods for treating cryptosporidiosis using triazolopyridazines
|
|
AU2016257179A1
(en)
|
2015-05-05 |
2017-11-02 |
Pfizer Inc. |
2-thiopyrimidinones
|
|
SG10201912684TA
(en)
*
|
2015-06-25 |
2020-03-30 |
Taiho Pharmaceutical Co Ltd |
Therapeutic agent for fibrosis
|
|
WO2017007756A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc |
Hetero-halo inhibitors of histone deacetylase
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
CA3001974A1
(en)
|
2015-10-14 |
2017-04-20 |
Bristol-Myers Squibb Company |
2,4-dihydroxy-nicotinamides as apj agonists
|
|
EP3383860B1
(en)
|
2015-12-04 |
2021-01-20 |
Bristol-Myers Squibb Company |
Apelin receptor agonists and methods of use
|
|
TW201725203A
(zh)
|
2015-12-16 |
2017-07-16 |
必治妥美雅史谷比公司 |
作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮
|
|
SG11201808163WA
(en)
|
2016-03-24 |
2018-10-30 |
Bristol Myers Squibb Co |
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
HUE057849T2
(hu)
|
2017-01-11 |
2022-06-28 |
Alkermes Inc |
Hiszton deacetiláz biciklusos gátlói
|
|
WO2018151177A1
(ja)
|
2017-02-15 |
2018-08-23 |
大鵬薬品工業株式会社 |
医薬組成物
|
|
EP3632904B1
(en)
*
|
2017-05-26 |
2022-04-20 |
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
Urat1 inhibitors for promoting uric acid excretion
|
|
EP3652165B1
(en)
*
|
2017-07-12 |
2021-08-25 |
Bristol-Myers Squibb Company |
Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
|
|
LT3664802T
(lt)
|
2017-08-07 |
2022-06-27 |
Alkermes, Inc. |
Bicikliniai histonų deacetilazės inhibitoriai
|
|
JP7074760B2
(ja)
|
2017-09-08 |
2022-05-24 |
大鵬薬品工業株式会社 |
抗腫瘍剤及び抗腫瘍効果増強剤
|
|
EP3765459A1
(en)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
DK4031547T3
(da)
|
2019-09-18 |
2024-09-09 |
Takeda Pharmaceuticals Co |
Plasmakallikreininhibitorer og anvendelser deraf
|
|
TR202009388A1
(tr)
*
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
US12378229B2
(en)
|
2021-02-02 |
2025-08-05 |
Liminal Biosciences Limited |
GPR84 antagonists and uses thereof
|
|
US20240199613A1
(en)
*
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|